Langerhans cell histiocytosis and Erdheim–Chester disease
- 1 January 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Rheumatology
- Vol. 24 (1), 90-96
- https://doi.org/10.1097/bor.0b013e32834db53e
Abstract
To provide an updated overview of the pathogenesis and treatment of Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD). There is ongoing debate as to the exact pathogenesis of these disorders and their classification as reactive versus neoplastic. Proinflammatory cytokines are known to play a role in both LCH and ECD and strengthen the hypothesis that, at least in part, they are disorders of immune dysregulation. The recent discovery of activating mutations in the proto-oncogene BRAF in a subset of LCH patients suggests that LCH is in fact a neoplastic disorder. Understanding of the mechanisms that promote proliferation and migration of histiocytes has led researchers to explore targeted immune-modulatory therapies for ECD. Similarly for LCH, alternative chemotherapeutic agents and reduced-intensity hematopoietic stem cell transplant are being evaluated for refractory disease. More research is needed to better understand the cause of these disorders and may help in identifying new targeted therapies, particularly for patients with refractory or relapsed disease. Multinational trials are ongoing for LCH and are urgently needed for ECD.Keywords
This publication has 57 references indexed in Scilit:
- Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in JapanPediatric Blood & Cancer, 2010
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- Chemotherapy and interferon-α treatment of Erdheim-chester diseasePediatric Blood & Cancer, 2010
- Interleukin-17A is not expressed by CD207+ cells in Langerhans cell histiocytosis lesionsNature Medicine, 2009
- Treatment of Refractory Langerhans Cell Histiocytosis (LCH) With a Combination of 2-Chlorodeoxyadenosine and Cytosine ArabinosideJournal of Pediatric Hematology/Oncology, 2009
- Imatinib mesylate for platelet-derived growth factor receptor-beta–positive Erdheim-Chester histiocytosisBlood, 2008
- Multisystem Erdheim‐Chester disease; a unique presentation with liver and axial skeletal involvementBritish Journal of Haematology, 2007
- Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunctionEuropean Journal of Cancer, 2005
- Langerhans cell histiocytosis of the female genital tract: A literature reviewInternational Journal of Gynecologic Cancer, 2003
- An Electron Microscope Study of Basal Melanocytes and High-Level Clear Cells (Langerhans Cells) in Vitiligo**From the Chester Beatty Research Institute, Royal Cancer Hospital, London, S.W. 3, and the Departments of Anatomy, and Dermatology, St. Mary's Hospital Medical School (University of London) London, W. 2, England.Journal of Investigative Dermatology, 1961